[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gout-flare\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gout-flare":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,72,123,148,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637588","24-week-recurrence-rate-of-gout-following-firsekibart-treatment-100637588",false,"NCT07625514","24-Week Recurrence Rate of Gout Following Firsekibart Treatment","The 24-Week Recurrence Rate of Acute Gouty Arthritis in Patients Treated With Firsekibart: A Multicenter, Prospective, Real-World Study","Inclusion Criteria:\n\n1. Age 18 to 75 years (inclusive), male or female;\n2. Meet the 2015 ACR\u002FEULAR Gout Classification Criteria;\n3. Two or more acute gout flares within a year;\n4. In the acute phase of a gout flare;\n5. Voluntarily signed the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. History of hypersensitivity to the study drug or similar classes of drugs;\n2. Pregnant or breastfeeding women;\n3. History of clinically significant diseases, including: Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) \\\u003C 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs;History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG ;\n4. Confirmed active tuberculosis infection;\n5. History of severe immunodeficiency, including positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases;\n6. Presence of infection requiring systemic treatment within 7 days prior to screening;\n7. Laboratory abnormalities at screening as follows: White blood cellcount or absolute neutrophil count below the lower limit of normal at the study site; Platelet count ≤100×10\\^9\u002FL; Total bilirubin \\> 1.5 times ULN (Upper Limit of Normal); AST\u002FALT \\> 3 times ULN; Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m²; Triglycerides \\> 5.7 mmol\u002FL;\n8. Any other conditions that, in the opinion of the investigator, may affect the evaluation of efficacy or safety in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},264,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study Objective: To evaluate the 24-week recurrence rate and safety of Firsekibart in patients with acute gouty arthritis in a real-world clinical setting.\n\nStudy Methods: This study utilizes a multicenter, prospective, observational, real-world study design. The study plans to enroll all cases that receive Firsekibart for the first time and meet the inclusion and exclusion criteria between March 1, 2026, and February 28, 2029, with a follow-up period of 24 weeks. This study will not intervene in clinical treatment regimens; it will solely record and analyze the diagnosis and treatment data that actually occur.\n\nStudy Outcomes: Primary Outcome: The proportion of patients with at least one gout recurrence (flare) at 24 weeks.Secondary Outcomes: 1. Average number of gout recurrences over 24 weeks; 2. Time to the first gout recurrence; 3. Duration of the first gout recurrence; 4. Incidence of adverse events (AEs) and serious adverse events (SAEs).",[27],"Gout Flare","NOT_YET_RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":21},"2026-05-07",{"date":36,"type":21},"2029-08-28",{"name":38,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",11,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100325992","home-hospital-for-suddenly-ill-adults-100325992","NCT03524222","Home Hospital for Suddenly Ill Adults","Home Hospital for Suddenly Ill Adults: A Clinical Trial","Inclusion Criteria:\n\n* Resides within either a 5-mile or 20 minute driving radius of emergency department\n* Has capacity to consent to study OR can assent to study and has proxy who can consent\n* \\>= 18 years-old\n* Can identify a potential caregiver who agrees to stay with patient for first 24 hours of admission. Caregiver must be competent to call care team if a problem is evident to her\u002Fhim. After 24 hours, this caregiver should be available for as-needed spot checks on the patient. This criterion may be waived for highly competent patients at the patient and clinician's discretion.\n* Primary or possible diagnosis of cellulitis, heart failure, complicated urinary tract infection, pneumonia, COPD\u002Fasthma, other infection, chronic kidney disease, malignant pain, diabetes and its complications, gout flare, hypertensive urgency, previously diagnosed atrial fibrillation with rapid ventricular response, anticoagulation needs, or a patient who desires only medical management that requires inpatient admission, as determined by the emergency room team.\n\nExclusion Criteria:\n\n* Undomiciled\n* No working heat (October-April), no working air conditioning if forecast \\> 80°F (June-September), or no running water\n* On methadone requiring daily pickup of medication\n* In police custody\n* Resides in facility that provides on-site medical care (e.g., skilled nursing facility)\n* Domestic violence screen positive\n* Acute delirium, as determined by the Confusion Assessment Method\n* Cannot establish peripheral access in emergency department (or access requires ultrasound guidance)\n* Secondary condition: end-stage renal disease, acute myocardial infarction, acute cerebral vascular accident, acute hemorrhage\n* Primary diagnosis requires multiple or routine administrations of intravenous narcotics for pain control\n* Cannot independently ambulate to bedside commode\n* As deemed by on-call medical doctor, patient likely to require any of the following procedures: computed tomography, magnetic resonance imaging, endoscopic procedure, blood transfusion, cardiac stress test, or surgery\n* High risk for clinical deterioration\n* Home hospital census is full (maximum 5 patients at any time)",{"count":49,"type":21},3000,[24],"The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improved patient experience.",[53,54,55,56,27,57,58,59,60],"Infection","Heart Failure","COPD","Asthma","Chronic Kidney Diseases","Hypertensive Urgency","Atrial Fibrillation Rapid","Anticoagulants; Increased","RECRUITING","2026-03-16",{"date":64,"type":32},"2026-03-17",{"date":66,"type":32},"2018-01-18",{"date":68,"type":21},"2031-09",{"name":70,"class":39},"Brigham and Women's Hospital",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100489857","phase-2-study-of-dapansutrile-tablets-in-subjects-with-an-acute-gout-flare-100489857","NCT05658575","Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","A Multi-Center Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","Inclusion Criteria:\n\n* Male and female subjects age 18 or older\n* Clinical diagnosis of gout according to the 2015 ACR\u002FEULAR Gout Classification Criteria:\n\nA) Diagnosis of gout must be confirmed in the target joint as indicated by either the presence of monosodium urate (MSU) crystals by microscopic evaluation of synovial fluid from the target joint or bursa OR by imaging evidence of urate deposition in the target joint or bursa at the Screening\u002FBaseline Visit\u002FStudy Day 1, or\n\nB) Documented history in the target joint or bursa ; or documented history of 2 or more gout flares in the previous 18 months\n\n* Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening\u002FBaseline Visit\n* Provide written informed consent and understand and comply with all trial requirements\n\nExclusion Criteria:\n\n* Presence of any palpable and visible tophi by physical examination\n* Has ≥ 4 joints with an acute gout flare at Screening\u002FBaseline\n* Presence of active rheumatoid arthritis or other acute inflammatory arthritis\n* Evidence\u002Fsuspicion of infectious\u002Fseptic arthritis\n* Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint\n* Known diagnosis of chronic kidney disease or known history of renal impairment\n* Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening\u002FBaseline\n* Active malignancy or recent malignancy with any systemic anti-cancer treatment\n* Has a hypersensitivity or allergy to OLT1177® or other drugs in its class\n* Hypersensitivity or allergy to paracetamol\u002Facetaminophen\n* Use of any prohibited concomitant medications\u002Ftherapies over the periods defined in the protocol or planned use of any prohibited concomitant medications\u002Ftherapies during the Treatment Period (including the use of paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or other pain medications within 12 hours prior to the Screening\u002F Baseline Visit\n* Use of any product containing paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication \\[paracetamol\u002Facetaminophen\\], which is permitted after completion of the first target joint pain assessment on Study Day 4",{"count":80,"type":21},300,[82,83],"PHASE2","PHASE3","The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.",[86,87,27,88,89,90,91],"Acute Gout Flare","Gout Attack","Gouty Arthritis","Gout","Arthritis","Joint Pain",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111],"gout","gouty arthritis","mono-articular arthritis","NLRP3","NLRP3 inhibitor","dapansutrile","OLT1177","joint pain","inflammation","gouty Inflammation","inflammasomes","IL-1 beta","IL-1 inflammation","autoinflammatory conditions","hyperuricemia","uric acid crystal","flare","small-molecule","therapeutic","2026-03-09",{"date":114,"type":32},"2026-03-11",{"date":116,"type":32},"2023-01-06",{"date":118,"type":21},"2027-01-31",{"name":120,"class":121},"Olatec Therapeutics LLC","INDUSTRY",40,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100619550","phase-4-purified-cortrophin-gel-efficacy-and-safety-study-of-2-dose-levels-in-patients-with-acute-gout-flares-100619550","NCT07346079","Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares","A Randomized, Multicenter, Double-blind, Efficacy and Safety Study of 2 Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares","Inclusion Criteria:\n\n* Signed informed consent to participate in this study\n* Male and female patients, aged 18-85 years\n* Meeting the 2015 Gout classification criteria of the ACR\u002FEULAR collaborative initiative\n* Onset of current acute gout flare within 5 days prior to study entry\n* Body mass index of less than or equal to 45 kg\u002Fm2\n* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)\n* History of ≥ 1 gout flares within the 12 months prior to study entry\n* The patient meets at least one of the following criteria for both NSAIDs and colchicine treatment options:\n* Minimum of one episode of being intolerant, or unresponsive to the treatment, see Appendices 2-4.\n* The investigator deems the patient is either contraindicated or inappropriate for the treatment. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication), see Appendices 2-4.\n* Patients must be willing and capable of using an electronic device (e.g., cellphone) and must have access to a cellphone to be able to complete surveys.\n\nExclusion Criteria:\n\n* Patients with scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, ocular herpes simplex, recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)), history of or the presence of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, uncontrolled diabetes type 1 or 2, or sensitivity to proteins derived from porcine sources.\n* Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.\n* Rheumatoid arthritis, evidence or suspicion of infectious\u002Fseptic arthritis, or other acute inflammatory arthritis.\n* Polyarticular gouty arthritis involving more than 4 joints.\n* Participation in another concurrent investigational study within 30 days of randomization or has taken an investigational drug within five times the half-life of that investigational drug has passed.\n* Previous inclusion in this study.\n* Presence of severe renal function impairment: estimated creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73m2 (CKD stages 4 and 5).\n* Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.\n* Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.\n* Prior or current treatment with any ACTH product.\n* Pregnant or nursing (lactating) women. Women of childbearing age are required to be using an acceptable method of contraception.\n* Patients taking urate-lowering therapy had to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.\n* Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol\u002Facetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor \\[TNF\\] inhibitors) within specified periods (see Appendix 5) prior to randomization.\n\n  * Vaccination within 30 days prior to study enrollment and during the study period.","90 Years",{"count":132,"type":21},150,[134],"PHASE4","This is a randomized, multicenter, double-blind, single administration study to investigate the efficacy and safety of 2 dosing regimens of Purified Cortrophin® Gel in the treatment of an acute gouty arthritis flare.\n\nThe study consists of three periods: an optional pre-screening period, a double-blind treatment period, and a 7-day follow-up period.\n\nThe treatment period is double-blind, and the patients will be randomized to treatment with 40 U Purified Cortrophin® Gel or 80 U Purified Cortrophin® Gel in a 1:1 ratio. Purified Cortrophin® Gel will be administered once (either subcutaneously or intramuscularly) on the first visit (Day 0; Visit 1) and surveyed after 24 hours (Day 1), 48 hours (Day 2), and 72 hours (Day 3; Visit 2) as well as on Day 7.",[137,27,89],"Gout Arthritis","2026-01-15",{"date":140,"type":32},"2026-01-20",{"date":142,"type":32},"2025-12-20",{"date":144,"type":21},"2027-08-31",{"name":146,"class":39},"Massachusetts General Hospital",1,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100604108","phase-2-safety-and-efficacy-of-abp-745-in-participants-with-an-acute-gout-flare-100604108","NCT07145229","Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare","A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare","Key Inclusion Criteria:\n\nSubjects are eligible for the study if they meet all of the following Inclusion Criteria:\n\n* Age 18-70 years old (inclusive), male or female.\n* Body mass index (BMI)18-40 kg\u002Fm2 (inclusive).\n* Medical history and current findings consistent with diagnosis of gouty arthritis.\n* Subjects must have experienced 2 or more gout flares within 12 months prior to screening.\n* Onset of an acute gout flare, within 6 months\n* Patients receiving ULT agents (such as allopurinol, febuxostat, probenecid, etc.) must be on stable doses of these drugs prior to first dose of study drug (and remain on the same dose throughout the Treatment Period).\n* Subjects agree to maintain a stable lifestyle (such as diet and exercise) during the study period.\n\nKey Exclusion Criteria:\n\nSubjects are excluded from the study if one or more of the following criteria are met:\n\n* Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.\n* Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.\n* Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.\n* Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.\n* Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.\n* Administration of muscle relaxants, central stimulants, barbiturates, etc. within 30 days prior to first dose of study drug or within 5 half-lives of the drug prior to the first dose of study drug, whichever is longer.\n* Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout).\n* Subjects with a current diagnosis or history of rheumatoid arthritis, psoriatic arthritis, evidence or suspicion of infectious\u002Fseptic arthritis, calcium pyrophosphate (CPP) crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis or any other demyelinating disease, or; major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.); with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion or Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening\n* Current anticoagulation therapy, thrombocytopenia, or diseases with a risk of thrombocytopenia, such as aplastic anemia, hypersplenism, or known hemorrhagic diseases like idiopathic thrombocytopenic purpura or hemophilia.\n* History of malignancy within 5 years prior to screening, excluding localized cancers such as basal cell carcinoma.\n* Presence of significant diseases, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160 or diastolic blood pressure ≥100 mmHg), congestive heart failure (New York Heart Association \\[NYHA\\] class III or above), uncontrolled type 1 or 2 diabetes mellitus (hemoglobin A1c \\[HbA1c\\] \\>8.5%). Inclusion will be determined by the Investigator based on the subject's specific condition.\n* Women of childbearing potential as defined by Appendix 2.\n* Experienced only no or mild gout-related pain prior to first dose of study drug.\n* Use of gout flare prophylaxis (e.g., colchicine, NSAIDs, prednisone\u002Fmethylprednisolone) at the time of randomization based on conversation with subject and self-reported.\n* Corona Virus Disease (COVID) vaccination in the 4 weeks prior to randomization.","70 Years",{"count":157,"type":21},380,[82],"A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.",[161,27,162,86],"Acute Gouty Arthritis","Gout Flares",[89,27,164,165,166],"Colchicine","Acute gout flare","ABP-745","2025-12-04",{"date":169,"type":32},"2025-12-08",{"date":171,"type":32},"2025-08-26",{"date":173,"type":21},"2026-06",{"name":175,"class":121},"Atom Therapeutics Co., Ltd",38,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":147},"100597676","developing-a-gout-action-plan-in-primary-care-setting-in-singapore-100597676","NCT07061587","Developing A Gout Action Plan in Primary Care Setting in Singapore","For patient participants:\n\nInclusion Criteria:\n\n* Adults who are 21 years old and above\n* Clinical diagnosis of gout as per ACE-EULAR 2015 criteria\n* Had at least an episode of gout exacerbation within the last 1 year\n* Able to speak and read English\n* Singapore citizens or permanent residents\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Mental disorders\n* Cognitive impairment\n* Hearing and\u002F or speech impairments\n* Pregnant\n* Known terminal illness\n* Unable to provide informed consent\n\nFor healthcare professionals:\n\nInclusion Criteria (for healthcare professionals):\n\n* Currently still in clinical practice\n* Manage gout in their clinical practice\n\nExclusion Criteria (for healthcare professionals):\n\n* Not involved in gout management in the practice\n* No longer in clinical practice","21 Years",{"count":185,"type":21},72,[24],"The goal of this clinical trial is to develop a gout action plan in primary care setting in Singapore among adult patients with gout, and to learn if the gout action plan can improve gout control.\n\nThe main questions it aims to answer are:\n\n* How do we develop a gout action plan in primary care setting in Singapore?\n* What is the feasibility and estimate effectiveness of the developed gout action plan?\n* Does gout action plan reduce frequency of gout flares in patients with gout?\n\nResearchers will compare gout action plan to usual clinical care to see whether gout action plan helps in improving gout control.\n\nParticipants in intervention arm will be:\n\n* given gout action plan and follow up for a course of 6 months\n* asked to keep track of their gout symptoms\n* follow up on the number of gout flares they have.",[189,27,190],"Gout; Hyperuricemia","Gout Chronic",[192,193],"Gout action plan","action plan","2025-07-02",{"date":196,"type":32},"2025-07-11",{"date":198,"type":21},"2025-08",{"date":200,"type":21},"2027-07",{"name":202,"class":39},"SingHealth Polyclinics"]